Lung Cancer Epidemiology and Management

Lung cancer is a malignant neoplasm of the lung and a leading cause of cancer death worldwide. It is broadly divided into non-small cell lung cancer (NSCLC), the large majority of cases, and small cell lung cancer (SCLC), with tobacco smoking the dominant cause. Understanding its epidemiology, molecular subtypes, staging, and the principles of screening and treatment is central to thoracic oncology.

Definition

Lung cancer is a malignant tumor arising from the epithelium of the lower respiratory tract, classified principally into non-small cell lung cancer and small cell lung cancer, and staged by tumor extent, nodal involvement, and metastasis.

Scope

This topic covers the descriptive epidemiology of lung cancer, its principal histologic and molecular subtypes, the rationale for low-dose CT screening in high-risk populations, and the general principles of treatment, including the shift toward molecularly targeted therapy and immunotherapy. It is a reference overview of how the disease is understood and how its evidence base is structured, not individualized clinical advice.

Core questions

• What distinguishes non-small cell from small cell lung cancer, and why does the distinction matter?
• How does tobacco exposure drive lung cancer epidemiology and prevention strategy?
• Which populations benefit from low-dose CT screening, and on what evidence?
• How have molecular profiling and immunotherapy reshaped management of advanced disease?

Key concepts

• Non-small cell lung cancer (adenocarcinoma, squamous cell carcinoma)
• Small cell lung cancer
• Tobacco smoking as the dominant risk factor
• Driver mutations (e.g., EGFR, ALK) and targeted therapy
• PD-L1 expression and immune checkpoint inhibition
• Low-dose CT screening
• TNM staging of the lung

Mechanisms

Most lung cancers arise from accumulated carcinogen-induced genetic damage, classically from tobacco smoke, producing either non-small cell or small cell histology. A subset of NSCLC, particularly adenocarcinomas and especially in never-smokers, is driven by specific oncogenic alterations such as EGFR mutations or ALK rearrangements that can be targeted pharmacologically; the discovery that EGFR-mutant tumors respond to EGFR inhibitors was a foundational example of biomarker-driven therapy (Paez et al., 2004). Tumor expression of PD-L1 and the broader interaction with the immune system underlie the activity of immune checkpoint inhibitors in suitable patients (Reck et al., 2016; Thai et al., 2021).

Clinical relevance

Lung cancer illustrates how a single anatomic site spans distinct histologies and molecular subtypes that carry different prognoses and evidence bases, and how prevention, screening, and systemic therapy each contribute to outcomes. This entry describes those principles and the supporting evidence; it does not provide individualized diagnostic or treatment recommendations.

Epidemiology

Lung cancer is among the most commonly diagnosed cancers and the leading cause of cancer mortality globally, with incidence patterns closely tracking historical tobacco use and varying by region and sex (Bray et al., 2024). Most cases are attributable to smoking, and incidence trends have shifted over time with tobacco control; a smaller but important fraction occurs in never-smokers and is enriched for targetable driver mutations (Thai et al., 2021).

Evidence & guidelines

Randomized evidence supports low-dose CT screening to reduce lung-cancer mortality in defined high-risk populations, as shown by the National Lung Screening Trial (NLST, 2011). For advanced disease, randomized trials established molecularly targeted agents for tumors with driver mutations and immune checkpoint inhibitors for PD-L1-expressing tumors, which together transformed first-line management (Paez et al., 2004; Reck et al., 2016). Contemporary clinical practice guidelines synthesize this evidence; specifics evolve and should be read in current guideline sources.

History

Lung cancer rose dramatically through the twentieth century in parallel with cigarette smoking, and case-control and cohort studies established tobacco as the principal cause. Treatment was long dominated by surgery, radiotherapy, and cytotoxic chemotherapy; the 2000s brought molecular characterization of driver mutations and targeted therapy, followed in the 2010s by immune checkpoint inhibition, reframing the disease as a set of molecularly defined entities.

Debates

How broadly should low-dose CT screening be applied?

Screening reduces lung-cancer mortality in high-risk groups but raises questions of eligibility thresholds, false positives, overdiagnosis, and implementation, so the optimal target population and program design remain actively discussed.

Seminal works

• nlst-2011
• paez-2004
• reck-2016
• thai-2021

Frequently asked questions

What is the difference between non-small cell and small cell lung cancer?

Non-small cell lung cancer (including adenocarcinoma and squamous cell carcinoma) makes up most cases and is staged and treated differently from small cell lung cancer, which is more aggressive and strongly associated with smoking; the distinction guides how the evidence base is organized.

Why is screening for lung cancer limited to certain groups?

Randomized evidence showed mortality benefit from low-dose CT screening in people at high risk based on age and smoking history; outside such high-risk groups the balance of benefits and harms, including false positives and overdiagnosis, is less favorable.